Investor Presentaiton

Some of Eurofins' Innovations: Becoming Leader in Non- Invasive Prenatal Testing (NIPT) in Europe and Japan eurofins Eurofins is the No. 1 player in the fast growing European NIPT market with ca. 150,000 non-invasive prenatal tests performed per year in 2020 & 2019 vs. ca. 100,000 tests in 2018 Eurofins offer a very comprehensive and innovative portfolio of tests in that market - from trisomy 21 to rare chromosome abnormalities (RCAs) In August 2020, Eurofins acquired GeneTech Inc. and became the market leader in NIPT in Japan 9 different screening options available Option 1 Option 2 Option 3 Option 4 Option 5 Option 6 Option 7 Option 8 Option 9 T21 T13, T18 T9, T16 all other foetal chromosomal anomalies SCA1 22q11.2 micro- deletion 6 micro- deletions 2 9 micro- deletions 3 9 micro- deletions single gene disorders foetal gender 1 Sex Chromosome Anomalies (SCA): Turner-Syndrome, Triple X-Syndrome, Klinefelter-Syndrome, XYY-Syndrome 2 DiGeorge syndrome (22q11.2), 2Cri-du-Chat syndrome (5p15.3), Prader-Willi syndrome (15q11.2), Angelman syndrome (15q11.2) and 1p36 microdeletion, Wolf-Hirschhorn syndrome (4p16.3) 3 include the 6 above plus Jacobsen syndrome (11q23), Langer-Giedion syndrome (8q24.11-q24.13) and Smith-Magenis syndrome (17p11.2) 4 Screens for inherited and de novo single-gene disorders. Inherited genetic disorders screened are: cystic fibrosis, beta-thalassemia, sickle cell anemia and autosomal recessive deafness. De novo disorders screened can cause skeletal dysplasia, cardiac defects, multiple congenital anomalies, autism, epilepsy and/or intellectual disability 13

View entire presentation